Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Wick

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Biochemical Pharmacology|February 1, 1985
Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamineG B FitzGerald, M M Wick
Journal of Pharmaceutical Sciences|July 1, 1987
Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrileM M Wick, G B FitzGerald
JAMA|March 29, 1976
Bronchorrhea responsive to aerosolized atropineM M Wick, R H Ingram
Anti-Cancer Drug Design|June 1, 1989
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinomaG B FitzGerald, M M Wick
JAMA|August 11, 1978
Levodopa therapy and malignant melanomaA J Sober, M M Wick
The Journal of Investigative Dermatology|February 1, 1983
3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymeraseG B FitzGerald, M M Wick
The Journal of Investigative Dermatology|January 1, 1987
Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinomaG B FitzGerald, M M Wick
Clinics in Dermatology|January 1, 1993
Bowen's diseaseM M Lee, M M Wick
CA: a Cancer Journal for Clinicians|July 1, 1990
Bowen's diseaseM M Lee, M M Wick
The Journal of Investigative Dermatology|February 1, 1979
Selective toxicity of 6-hydroxydopa for melanoma cellsM M Wick, L Byers, J Ratliff
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|February 1, 1985
Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamineG B FitzGerald, M M Wick
Journal of Pharmaceutical Sciences|July 1, 1987
Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrileM M Wick, G B FitzGerald
JAMA|March 29, 1976
Bronchorrhea responsive to aerosolized atropineM M Wick, R H Ingram
Anti-Cancer Drug Design|June 1, 1989
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinomaG B FitzGerald, M M Wick
JAMA|August 11, 1978
Levodopa therapy and malignant melanomaA J Sober, M M Wick
The Journal of Investigative Dermatology|February 1, 1983
3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymeraseG B FitzGerald, M M Wick
The Journal of Investigative Dermatology|January 1, 1987
Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinomaG B FitzGerald, M M Wick
Clinics in Dermatology|January 1, 1993
Bowen's diseaseM M Lee, M M Wick
CA: a Cancer Journal for Clinicians|July 1, 1990
Bowen's diseaseM M Lee, M M Wick
The Journal of Investigative Dermatology|February 1, 1979
Selective toxicity of 6-hydroxydopa for melanoma cellsM M Wick, L Byers, J Ratliff
Pageof 7